Insider Selling: Xencor, Inc. (NASDAQ:XNCR) Director Sells 2,215 Shares of Stock

Xencor, Inc. (NASDAQ:XNCR - Get Free Report) Director Alan Bruce Montgomery sold 2,215 shares of the company's stock in a transaction on Monday, June 16th. The shares were sold at an average price of $9.22, for a total value of $20,422.30. Following the completion of the sale, the director now directly owns 20,611 shares in the company, valued at $190,033.42. This trade represents a 9.70% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Xencor Trading Down 1.5%

NASDAQ:XNCR traded down $0.14 during trading hours on Monday, reaching $9.05. 570,953 shares of the company were exchanged, compared to its average volume of 667,223. The firm has a market cap of $644.10 million, a price-to-earnings ratio of -2.83 and a beta of 0.87. The stock has a 50 day simple moving average of $9.08 and a 200 day simple moving average of $14.92. Xencor, Inc. has a 52-week low of $7.16 and a 52-week high of $27.24. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.23 and a quick ratio of 6.23.

Xencor (NASDAQ:XNCR - Get Free Report) last issued its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.06). Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The firm had revenue of $32.73 million during the quarter, compared to analysts' expectations of $23.44 million. During the same period last year, the business posted ($1.11) earnings per share. The company's quarterly revenue was up 104.6% compared to the same quarter last year. As a group, analysts predict that Xencor, Inc. will post -3.68 EPS for the current year.

Hedge Funds Weigh In On Xencor

A number of large investors have recently modified their holdings of the company. Sterling Capital Management LLC lifted its position in shares of Xencor by 732.4% during the fourth quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 1,040 shares in the last quarter. New York State Teachers Retirement System grew its stake in shares of Xencor by 2.1% during the first quarter. New York State Teachers Retirement System now owns 59,326 shares of the biopharmaceutical company's stock valued at $631,000 after acquiring an additional 1,200 shares in the last quarter. Summit Investment Advisors Inc. lifted its stake in shares of Xencor by 22.2% in the fourth quarter. Summit Investment Advisors Inc. now owns 7,045 shares of the biopharmaceutical company's stock worth $162,000 after acquiring an additional 1,282 shares in the last quarter. PNC Financial Services Group Inc. lifted its stake in shares of Xencor by 49.4% in the fourth quarter. PNC Financial Services Group Inc. now owns 4,041 shares of the biopharmaceutical company's stock worth $93,000 after acquiring an additional 1,337 shares in the last quarter. Finally, Sanctuary Advisors LLC boosted its holdings in Xencor by 5.3% in the fourth quarter. Sanctuary Advisors LLC now owns 28,263 shares of the biopharmaceutical company's stock valued at $649,000 after purchasing an additional 1,432 shares during the last quarter.

Wall Street Analyst Weigh In

XNCR has been the topic of a number of research reports. William Blair assumed coverage on shares of Xencor in a research note on Monday, April 21st. They issued an "outperform" rating on the stock. Wall Street Zen lowered Xencor from a "hold" rating to a "sell" rating in a research note on Friday, March 14th. Barclays reduced their target price on shares of Xencor from $22.00 to $6.00 and set an "underweight" rating on the stock in a report on Thursday, May 8th. Wells Fargo & Company lowered their price target on shares of Xencor from $37.00 to $33.00 and set an "overweight" rating for the company in a report on Friday, February 28th. Finally, Wedbush reissued an "outperform" rating and set a $31.00 price objective on shares of Xencor in a research note on Wednesday, April 30th. Two research analysts have rated the stock with a sell rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, Xencor presently has an average rating of "Moderate Buy" and an average price target of $28.00.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.